These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30191087)

  • 1. Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.
    D'Abreu A; Friedman JH
    Tremor Other Hyperkinet Mov (N Y); 2018; 8():570. PubMed ID: 30191087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia and withdrawal emergent syndrome in children.
    Mejia NI; Jankovic J
    Expert Rev Neurother; 2010 Jun; 10(6):893-901. PubMed ID: 20518606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply to: Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.
    Walker RH
    Tremor Other Hyperkinet Mov (N Y); 2019; 9():626. PubMed ID: 30783553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
    Lévesque C; Hernandez G; Mahmoudi S; Calon F; Gasparini F; Gomez-Mancilla B; Blanchet PJ; Lévesque D
    Neuroscience; 2017 Oct; 361():43-57. PubMed ID: 28790021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tardive dyskinesia].
    Zalyalova ZA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):25-31. PubMed ID: 37490662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Letter to the Editor.
    Friedman JH; D'Abreu A
    Tremor Other Hyperkinet Mov (N Y); 2019; 9():630. PubMed ID: 30783554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive gait.
    Kuo SH; Jankovic J
    Clin Neurol Neurosurg; 2008 Feb; 110(2):198-201. PubMed ID: 17997030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Focused Update on Tardive Dyskinesia.
    Blanchet PJ
    Can J Neurol Sci; 2020 Nov; 47(6):747-755. PubMed ID: 32624027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results.
    Szota AM; Scheel-Krüger J
    Behav Pharmacol; 2020 Sep; 31(6):511-523. PubMed ID: 32459694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.
    Barer Y; Ribalov R; Yaari A; Maor R; Arow Q; Logan J; Chodick G; Arkadir D; Eitan R
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):454-460. PubMed ID: 36018237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.